Hepatectomy Clinical Trials

• Male or female, 18-80 years of age.

• Patients volunteered to join the study and signed informed consent, with good compliance and follow-up.

• Primary colorectal tumors can be radically resected or resected and histopathologically diagnosed as colorectal cancer.

• Patients with synchronous or metachronous diagnosis of liver metastasis and extrahepatic metastasis by computed tomography (CT) or magnetic resonance imaging (MRI).Extrahepatic metastases are stable and controllable as determined by Multi-disciplinary Treatment (MDT).

• Patients receive only first- or second-line systemic therapy.

• Radical local treatment can be performed after MDT evaluation, and the indications at least meet the following one:

‣ Hepatectomy: liver metastases can be completely (R0) removed and required to retain sufficient functional liver tissue;

⁃ Ablation therapy: The maximum diameter of liver metastases\<3 cm, and the maximum number of ablation ≤ 5.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

• Life expectancy of at least 3 months.

• Child-Pugh score ≤ 7.

• Laboratory routine examination (blood routine, liver and kidney function, coagulation function, etc.) no significant abnormalities:

‣ Absolute neutrophil count (ANC) ≥ 1.5×10\^9/l;

⁃ Platelet count (PLT) ≥ 100\*10\^9/l;

⁃ Hemoglobin ≥ 9g/dl;

⁃ TBIL\<1.5 times the upper limit of normal (ULN);

⁃ ALT and AST\< 5\*ULN;

⁃ Serum creatinine ≤ 1.5 \* ULN or Creatinine clearance\> 50 ml/min;

⁃ Albumin \> 30 g/l.